ResMed Inc. (RMD) Analysts See $0.78 EPS

December 29, 2017 - By Vivian Park

 ResMed Inc. (RMD) Analysts See $0.78 EPS
Investors sentiment increased to 1.35 in Q3 2017. Its up 0.47, from 0.88 in 2017Q2. It is positive, as 30 investors sold ResMed Inc. shares while 97 reduced holdings. 61 funds opened positions while 111 raised stakes. 86.71 million shares or 1.22% more from 85.67 million shares in 2017Q2 were reported.
Copeland Mngmt Lc has invested 0.73% in ResMed Inc. (NYSE:RMD). Hudson Valley Invest Advsr Adv invested in 57,764 shares or 1.5% of the stock. Prudential Financial Inc holds 185,236 shares or 0.02% of its portfolio. Strs Ohio reported 20,789 shares. Asset Management One invested 0.05% of its portfolio in ResMed Inc. (NYSE:RMD). Sumitomo Mitsui Trust has 379,209 shares for 0.04% of their portfolio. 56,973 were accumulated by Us Comml Bank De. Clinton Gp Incorporated holds 6,163 shares or 0.05% of its portfolio. Security National Tru holds 0.1% or 3,850 shares. 16,496 were reported by Ontario Teachers Pension Plan Board. Sumitomo Mitsui Asset Mgmt invested in 0.01% or 10,526 shares. Public Employees Retirement Of Ohio reported 0.02% in ResMed Inc. (NYSE:RMD). Moreover, Frontier Investment Mngmt Com has 0.02% invested in ResMed Inc. (NYSE:RMD). Moreover, Mai has 0.06% invested in ResMed Inc. (NYSE:RMD) for 13,450 shares. North Star Asset Mngmt Incorporated has 0.22% invested in ResMed Inc. (NYSE:RMD) for 29,303 shares.

Since August 3, 2017, it had 0 insider purchases, and 9 selling transactions for $8.01 million activity. PENDARVIS DAVID sold $458,844 worth of stock. On Friday, September 1 Sandercock Brett sold $96,950 worth of ResMed Inc. (NYSE:RMD) or 1,250 shares. 24,390 shares were sold by SULPIZIO RICHARD, worth $1.80 million on Wednesday, August 9.

Analysts expect ResMed Inc. (NYSE:RMD) to report $0.78 EPS on January, 22.They anticipate $0.05 EPS change or 6.85 % from last quarter’s $0.73 EPS. RMD’s profit would be $110.68 million giving it 27.39 P/E if the $0.78 EPS is correct. After having $0.66 EPS previously, ResMed Inc.’s analysts see 18.18 % EPS growth. The stock decreased 0.93% or $0.8 during the last trading session, reaching $85.46. About 56,593 shares traded. ResMed Inc. (NYSE:RMD) has risen 20.34% since December 29, 2016 and is uptrending. It has outperformed by 3.64% the S&P500.

ResMed Inc. (NYSE:RMD) Ratings Coverage

Among 14 analysts covering ResMed Inc (NYSE:RMD), 4 have Buy rating, 4 Sell and 6 Hold. Therefore 29% are positive. ResMed Inc had 41 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of ResMed Inc. (NYSE:RMD) earned “Neutral” rating by Piper Jaffray on Wednesday, April 27. The firm earned “Hold” rating on Monday, May 15 by BMO Capital Markets. Credit Suisse downgraded the stock to “Neutral” rating in Wednesday, August 2 report. Needham downgraded ResMed Inc. (NYSE:RMD) on Monday, June 27 to “Underperform” rating. The stock of ResMed Inc. (NYSE:RMD) earned “Market Perform” rating by BMO Capital Markets on Friday, October 27. Citigroup upgraded the stock to “Buy” rating in Wednesday, August 2 report. The stock has “Neutral” rating by JP Morgan on Tuesday, October 4. The rating was downgraded by Needham on Thursday, December 17 to “Hold”. The rating was maintained by Jefferies with “Sell” on Friday, June 2. As per Friday, October 27, the company rating was maintained by Barclays Capital.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company has market cap of $12.13 billion. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud software informatics solutions to manage patient outcomes, as well as provides customer and business processes. It has a 34.74 P/E ratio. The firm also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators.

More news for ResMed Inc. (NYSE:RMD) were recently published by:, which released: “NZ’s Fisher & Paykel sues Resmed in Australia over patent dispute” on December 12, 2017.‘s article titled: “ResMed Inc. (CHESS) (ASX:RMD) Stock Consolidating” and published on December 27, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.